Moxetumomab pasudotox
Moxetumomab pasudotox is a recombinant immunotoxin used in the treatment of certain types of cancer. It is specifically designed to target and kill cancer cells expressing the CD22 antigen, which is commonly found on the surface of B-cell malignancies.
Mechanism of Action[edit | edit source]
Moxetumomab pasudotox is composed of an antibody fragment that binds to the CD22 antigen and a toxin derived from Pseudomonas exotoxin A. Upon binding to the CD22 antigen on the surface of cancer cells, the drug is internalized, and the toxin component is released inside the cell. This leads to the inhibition of protein synthesis and ultimately induces apoptosis (programmed cell death) in the targeted cancer cells.
Indications[edit | edit source]
Moxetumomab pasudotox is primarily indicated for the treatment of hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Administration[edit | edit source]
The drug is administered via intravenous infusion over a period of 30 minutes. The recommended dosage and treatment schedule are determined based on the patient's body surface area and overall health condition.
Side Effects[edit | edit source]
Common side effects of moxetumomab pasudotox include:
Serious side effects may include:
Clinical Trials[edit | edit source]
Moxetumomab pasudotox has undergone several clinical trials to evaluate its efficacy and safety in patients with hairy cell leukemia and other B-cell malignancies. These trials have demonstrated significant clinical activity and manageable toxicity profiles.
Approval[edit | edit source]
The U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox in September 2018 for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies.
Related Pages[edit | edit source]
Categories[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
